BioMedNewsBreaks Archive - Page 68 of 249

MondayJun 24, 2024 2:03 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming H.C. Wainwright Neuro Perspectives Virtual Conference

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will be featured at this week’s H.C. Wainwright’s Fifth Annual Neuro Perspectives Virtual Conference. According to the announcement, Clene management will be presenting a fireside chat and will host one-on-one investor meetings during the June 27, 2024, online event. The presentation will be available upon demand the day of the conference, with a webcast of the presentation also found on the Clene website. To…

FridayJun 21, 2024 3:42 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents New Preliminary Data Demonstrating Potential of CNM-Au8(R) as Treatment for Rett Syndrome

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). Clene today announced that Karen Ho, Ph.D., the company’s vice president of translational medicine, presented new, preliminary data demonstrating the potential of CNM-Au8(R) as a treatment for Rett Syndrome, a severe, rare pediatric neurologic disorder. Dr. Ho unveiled the data in oral and poster presentations on June 19 at the International Rett Syndrome Foundation 2024 Annual Meeting…

ThursdayJun 20, 2024 3:57 pm

BioMedNewsBreaks — Astrotech Corporation’s (NASDAQ: ASTC) TRACER 1000(TM) Receives ‘Approved’ Status on Air Cargo Security Technology List

Astrotech (NASDAQ: ASTC) and its wholly owned subsidiary, 1st Detect Corporation, today announced that the U.S. Transportation Security Administration (“TSA”) has approved the TRACER 1000(TM) for the Air Cargo Security Technology List (“ACSTL”) following thorough assessment by the TSA QG2 Technical Review Panel (“TRP”). Following the approval, regulated parties in the U.S., such as the air cargo market, which are required to use the ACSTL, can now purchase the TRACER 1000. This approval, the announcement noted, advances the TRACER 1000 to Stage II testing. Once the field testing is successfully completed, the TRACER 1000 will move to the “Qualified” section…

ThursdayJun 20, 2024 11:11 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Shares Update on Its AVERSA(TM) Fentanyl Product Development Program

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, today provided an update on its AVERSA(TM) Fentanyl product development program. This comes as the company plans to complete scale-up of the commercial manufacturing process and move towards the single Phase 1 human abuse potential study prior to a New Drug Application (“NDA”) filing. According to the update, Nutriband is currently working with its partner Kindeva Drug Delivery to develop the commercial scale manufacturing process for the final product, which will incorporate Nutriband’s AVERSA(TM) abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. The update noted…

ThursdayJun 20, 2024 9:42 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Extended Survival Data to Support CNM-Au8® as Potential Treatment for ALS at 2024 ENCALS Meeting

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, presented new long-term CNM-Au8 treatment results for survival and neurofilament light (“NfL”) levels from the HEALEY ALS Platform Trial open label extension (“OLE”) at the European Network for the Cure of ALS (“ENCALS”) meeting in Stockholm, Sweden. Entitled “Long-Term CNM-Au8 Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,” the presentation data highlights up to 42 months (3.5 years) of survival…

TuesdayJun 18, 2024 12:44 pm

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), will be presenting results from its latest Alzheimer’s study at the Alzheimer’s Association International Conference(R) 2024 (“AAIC”). The conference is slated to run from July 28–Aug. 1, 2024, in Philadelphia as well as online. According to the announcement, Annovis Bio senior VP of research & development Dr. Cheng Fang will present an extended 45-minute session at the conference; the presentation is scheduled to begin at 8 a.m. on July 31. He will be joined by Kathleen A. Welsh-Bohmer, PhD,…

MondayJun 17, 2024 10:36 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc.(NASDAQ: CNSP) Enters in Purchase Agreements, Announces Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The agreements are for the purchase and sale of 366,000 shares of common stock, or common stock equivalents in lieu thereof, as part of registered direct offering and warrants to purchase up to 366,000 shares of common stock in a concurrent private placement. The shares will be offered at a combined purchase price of $3.75 per share. According to the announcement, the warrants…

FridayJun 14, 2024 1:20 pm

BioMedNewsBreaks — Astrotech Corp. (NASDAQ: ASTC) Subsidiary Partners with Multistate Testing Lab to Market Proprietary AgLAB Solutions

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its subsidiary, AgLAB, have entered into a master lease agreement with SC Labs; the companies are working together to jointly market the AgLAB 1000-D2(TM) mass spectrometer and the AgLAB Maximum Value Process testing method to SC Labs customers. AgLAB has pioneered applications featuring the Astrotech Mass Spectrometer Technology that specifically target the hemp and cannabis markets while SC Labs, one of the largest multistate cannabis and hemp-testing labs in the United States, delivers industry-leading, science-based innovations in cannabis and hemp testing. The partnership between the two entities extends SC Labs’ analytical services directly…

ThursdayJun 13, 2024 2:05 pm

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives LOI with European Investment Bank for Loan-to-Equity Conversion

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has received a nonbinding letter of intent (“LOI”) from the European Investment Bank (“EIB”). According to the announcement, the LOI contains terms for converting EIB's loan of approximately $27.6 million into equity in the form of prefunded warrants; the warrants, which will be exercisable into American Depositary Shares (“ADSs”), represent 19.5% of the fully diluted capital of the company as well as capped variable return mostly in the form of…

ThursdayJun 13, 2024 1:29 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Marks Major Milestone in Preparations for NDA Submission, Global Suramin Supply

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently completed its three registration/validation batches of PAX-101, an IV formulation of suramin. “This accomplishment marks a significant step toward submitting a New Drug Application (‘NDA’) to the U.S. Food and Drug Administration (‘FDA’) in the fourth quarter of 2024. This step paves the way for potential commercial availability in the U.S. of suramin, the sole form for treating stage 1 Human African Trypanosomiasis (‘HAT’) caused by Trypanosoma brucei rhodesiense. This disease, fatal and neglected, represents a critical healthcare challenge,” a recent article reads. “This completion of…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming H.C. Wainwright Neuro Perspectives Virtual Conference

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents New Preliminary Data Demonstrating Potential of CNM-Au8(R) as Treatment for Rett Syndrome

BioMedNewsBreaks — Astrotech Corporation’s (NASDAQ: ASTC) TRACER 1000(TM) Receives ‘Approved’ Status on Air Cargo Security Technology List

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Shares Update on Its AVERSA(TM) Fentanyl Product Development Program

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Extended Survival Data to Support CNM-Au8® as Potential Treatment for ALS at 2024 ENCALS Meeting

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024

BioMedNewsBreaks — CNS Pharmaceuticals Inc.(NASDAQ: CNSP) Enters in Purchase Agreements, Announces Pricing

BioMedNewsBreaks — Astrotech Corp. (NASDAQ: ASTC) Subsidiary Partners with Multistate Testing Lab to Market Proprietary AgLAB Solutions

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives LOI with European Investment Bank for Loan-to-Equity Conversion

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Marks Major Milestone in Preparations for NDA Submission, Global Suramin Supply

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search